LIMN vs IVF

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

LIMN

31.8
AI Score
VS
IVF Wins

IVF

43.0
AI Score

Investment Advisor Scores

LIMN

32score
Recommendation
SELL

IVF

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric LIMN IVF Winner
Net Income -2.53M 9.05M IVF
Operating Income -2.48M -6.63M LIMN
ROE -841.9% 71.9% IVF
ROA -74.4% 19.6% IVF
Total Assets 3.40M 46.08M IVF
Cash 3.02M 619,520 LIMN
Current Ratio 1.12 0.07 LIMN
Free Cash Flow -3.00M -3.16M LIMN

Relative Price Performance (Last 90 Days)

LIMN 1M: +3098.2% · 3M: +2451.5% IVF 1M: -4.0% · 3M: -35.0%

Current Technical Phase

LIMN

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (984.2% over 20 days), RSI 63

RSI (14): 63.5 · Price: $3.47

IVF

Markdown
Sell / avoid

Price below a falling SMA50 (slope -16.0%), weak momentum, RSI 43

RSI (14): 42.6 · Price: $0.97

Fundamentals Snapshot

Metric LIMN IVF
Market Cap
Forward P/E 0.0 -0.1
Trailing P/E 0.0
Revenue (TTM)
Revenue Growth 0.0% 0.2%
Gross Margin 0.4%
Operating Margin 0.0% -0.6%
EPS -24.68 363.47
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, IVF is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.